Astrazeneca Plc Adr Stock Performance
| AZN Stock | USD 77.60 1.09 1.42% |
On a scale of 0 to 100, AstraZeneca PLC holds a performance score of 18. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AstraZeneca PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding AstraZeneca PLC is expected to be smaller as well. Please check AstraZeneca PLC's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether AstraZeneca PLC's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC ADR are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, AstraZeneca PLC displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.42 | Five Day Return (0.12) | Year To Date Return 17.79 | Ten Year Return 125.84 | All Time Return 1.4 K |
Forward Dividend Yield 0.0203 | Payout Ratio | Last Split Factor 2:1 | Forward Dividend Rate 1.55 | Dividend Date 2025-03-24 |
1 | AstraZenecas metastatic breast cancer treatment gets EU recommendation | 02/28/2025 |
2 | Onos ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyos TURALIO Dominance DelveInsight | 03/04/2025 |
3 | Amgen Challenges Novo Nordisks Ozempic And Eli Lillys Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials | 03/06/2025 |
4 | IMFINZI -based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and... | 03/07/2025 |
5 | Amgen, Kyowa Kirins rocatinlimab trial for atopic dermatitis meets endpoints | 03/10/2025 |
6 | Diffblue Launches Test Review New Feature Gives Developers Versatility in Unit Testing Workflows | 03/11/2025 |
7 | INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies for COVID-19 | 03/13/2025 |
| Begin Period Cash Flow | 5.6 B |
AstraZeneca |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 6,532 in AstraZeneca PLC ADR on December 15, 2024 and sell it today you would earn a total of 1,228 from holding AstraZeneca PLC ADR or generate 18.8% return on investment over 90 days. AstraZeneca PLC ADR is generating 0.2951% of daily returns assuming volatility of 1.2401% on return distribution over 90 days investment horizon. In other words, 11% of stocks are less volatile than AstraZeneca, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AstraZeneca PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AstraZeneca PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AstraZeneca PLC ADR, and traders can use it to determine the average amount a AstraZeneca PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.238
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AZN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.24 actual daily | 11 89% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.24 actual daily | 18 82% of assets perform better |
Based on monthly moving average AstraZeneca PLC is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AstraZeneca PLC by adding it to a well-diversified portfolio.
AstraZeneca PLC Fundamentals Growth
AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0788 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 258.34 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 6.19 X | ||||
| Price To Sales | 4.39 X | ||||
| Revenue | 54.07 B | ||||
| Gross Profit | 44.44 B | ||||
| EBITDA | 17.12 B | ||||
| Net Income | 8.69 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 30.11 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 26.30 X | ||||
| Cash Flow From Operations | 11.86 B | ||||
| Earnings Per Share | 2.25 X | ||||
| Market Capitalization | 237.21 B | ||||
| Total Asset | 104.03 B | ||||
| Retained Earnings | 3.16 B | ||||
| Working Capital | (2.04 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
About AstraZeneca PLC Performance
By examining AstraZeneca PLC's fundamental ratios, stakeholders can obtain critical insights into AstraZeneca PLC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AstraZeneca PLC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 189.10 | 142.46 | |
| Return On Tangible Assets | 0.15 | 0.11 | |
| Return On Capital Employed | 0.13 | 0.24 | |
| Return On Assets | 0.07 | 0.10 | |
| Return On Equity | 0.17 | 0.34 |
Things to note about AstraZeneca PLC ADR performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AstraZeneca PLC ADR has 30.11 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return. | |
| AstraZeneca PLC ADR has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies for COVID-19 |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.567 | Dividend Share 3.1 | Earnings Share 2.25 | Revenue Per Share | Quarterly Revenue Growth 0.238 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.